Atossa Genetics Inc Stock Nasdaq
Equities
US04962H1005
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
07-02 | Atossa Therapeutics Names Heather Rees CFO | MT |
07-02 | Atossa Therapeutics, Inc. Appoints Heather Rees as Chief Financial Officer | CI |
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 137M 187M |
---|---|---|---|---|---|
Net income 2024 * | -30M -40.92M | Net income 2025 * | -35M -47.74M | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-4.54
x | P/E ratio 2025 * |
-3.96
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.9% |
Latest transcript on Atossa Genetics Inc
Managers | Title | Age | Since |
---|---|---|---|
Shu-Chih Chen
FOU | Founder | 62 | 08-11-30 |
Steven Quay
CEO | Chief Executive Officer | 73 | 08-11-30 |
Heather Rees
DFI | Director of Finance/CFO | 51 | 16-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Steven Quay
CEO | Chief Executive Officer | 73 | 08-11-30 |
Director/Board Member | 66 | 14-02-28 | |
H. Remmel
BRD | Director/Board Member | 72 | 12-01-31 |
1st Jan change | Capi. | |
---|---|---|
+18.97% | 45.34B | |
+41.98% | 40.42B | |
-10.06% | 37.92B | |
+31.15% | 31.75B | |
-7.79% | 27.71B | |
+13.32% | 26.52B | |
+43.05% | 13.96B | |
+31.28% | 12.44B | |
-7.41% | 11.26B |